SynthesisFuture oncology (London, England)2025
Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.
Elena Castro et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.